Business Context and Reporting Period
Company: Alphatec Holdings, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: December 17, 2009
Event: Entry into a Material Definitive Agreement to acquire Scient'x S.A., a global medical device company based in France specializing in surgical implants for spinal disorders.
Key Financial Metrics and Transaction Terms
- Acquisition Target: Approximately 94.8% of issued and outstanding shares of Scient'x S.A., with efforts to acquire the remaining 5.2% to reach 100% ownership.
- Consideration: Issuance of 24,000,000 shares of Alphatec common stock.
- Pro Forma Dilution: The new shares will constitute approximately 31.3% of Alphatec's voting stock following issuance (based on capital stock outstanding as of December 15, 2009).
- Termination Fee: Alphatec may be required to pay a termination fee of $3.2 million to HealthpointCapital under specified circumstances.
- Existing Ownership: HealthpointCapital and affiliates own approximately 39.4% of Alphatec's outstanding common stock as of December 15, 2009.
Note: This filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures for Alphatec or Scient'x.
Material Changes and Conditions
The transaction represents a significant expansion of Alphatec's operations through the acquisition of a foreign subsidiary. The closing is subject to several material conditions:
- Approval by holders of a majority of Alphatec's common stock at a special meeting.
- Receipt of required governmental approvals, including the expiration of the Hart-Scott-Rodino Act waiting period.
- Approval by NASDAQ for the listing of the shares to be issued.
- Expected closing date: End of the first quarter of 2010.
Guidance, Outlook, and Risks
- Management Commentary: A special committee of disinterested directors unanimously recommended the transaction. Financial advisor Thomas Weisel Partners LLC opined that the Share Purchase is fair from a financial point of view to Alphatec.
- Corporate Governance: A Corporate Governance Agreement was entered into with HealthpointCapital, restricting them from seeking to acquire additional Alphatec securities or participating in schemes to acquire the Company for a specified period, subject to exceptions.
- Registration Rights: Scient'x shareholders will receive demand and piggy-back registration rights for the shares issued, exercisable 90 to 135 days post-closing, subject to market value thresholds ($10 million or 3% of outstanding shares).
- Risks: The transaction is contingent on shareholder and regulatory approval. Failure to close could result in the payment of the $3.2 million termination fee.
Investor Verification Checklist
- Verify the final approval status of the transaction by Alphatec stockholders at the special meeting.
- Confirm the receipt of all necessary governmental and NASDAQ approvals.
- Review the upcoming Proxy Statement for detailed financial information regarding Scient'x and the full terms of the transaction.
- Monitor the actual number of shares issued, as the 24,000,000 figure is subject to reduction for fees and expenses.
- Assess the impact of the 31.3% pro forma dilution on existing shareholder voting power and earnings per share.